<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cyproterone and ethinyl estradiol (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cyproterone and ethinyl estradiol (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cyproterone and ethinyl estradiol (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11712" href="/d/html/11712.html" rel="external">see "Cyproterone and ethinyl estradiol (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866480"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cleo-35;</li>
<li>Cyestra-35;</li>
<li>Diane-35;</li>
<li>TARO-Cyproterone/Eth Estradiol;</li>
<li>TEVA-Cyproterone/Eth Estradiol</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F155861"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Acne Products;</li>
<li>
                        Estrogen and Progestin Combination</li></ul></div>
<div class="block doa drugH1Div" id="F155847"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris: Oral:</b> One tablet once daily for 21 days, followed by 7 days off; first cycle should begin on the first day of menstrual flow. Subsequent dosing cycles should begin on the same day of the week that the first cycle was begun regardless of presence of withdrawal bleeding. Discontinue therapy 3 to 4 cycles after symptoms have resolved. <b>Note:</b> Retreatment may be considered with recurrence of symptoms following therapy discontinuation. Therapy should not be interrupted for spotting or breakthrough bleeding; persistent or prolonged bleeding should be evaluated. Evaluate pregnancy status if menstruation does not occur during 7-day tablet-free interval; discontinue if pregnancy is suspected.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990246"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Based on available data, dosage adjustment is not needed.</p></div>
<div class="block doha drugH1Div" id="F50987388"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated.</p></div>
<div class="block dop drugH1Div" id="F50618912"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris:</b> Females: Oral: See adult dosing; not to be used prior to menarche.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51108743"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51108744"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Use is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F155819"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see Cyproterone monograph.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (2%), varicosity (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Chloasma (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast tenderness (7%), dysmenorrhea (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depressed mood (3%), dizziness (1%), headache (5%), nervousness (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Embolism of systemic artery (involving the extremities and spleen), flushing, hypertensive crisis, livedo reticularis, palpitations, superficial thrombophlebitis, thrombosis (sinus), venous thromboembolism (including deep vein thrombosis and pulmonary embolism) (Chen 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, allergic skin reaction, alopecia, atrophic striae, cellulitis, eczema, erythema nodosum, neurodermatitis, pruritus, skin discoloration (blue spots), skin photosensitivity, skin pigmentation, skin rash, subcutaneous nodule, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus, hyperprolactinemia, hyperthyroidism, menstrual disease</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, cholangitis, cholestasis, <i>Clostridioides difficile</i> colitis, diarrhea, flatulence, malignant neoplasm of the bile duct, pancreatitis, sialadenitis, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abortion (including missed abortion), cervical dysplasia, malignant neoplasm of breast, ovarian cyst, urinary tract infection, uterine fibroids, vaginitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute leukemia, hematoma (liver, subcapsular)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal transaminases, ascites, hepatic adenoma, hepatic carcinoma, hepatic focal nodular hyperplasia, hepatic neoplasm, hepatitis, hepatomegaly, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral thrombosis, cerebrovascular accident (Kromm 2014), chorea (hemichorea) (Sharmila 2015), confusion, depression, drowsiness, facial paresis, hydrocephalus (acute), hyperalgesia (hyperpathia), hypoesthesia, insomnia, manic reaction, migraine, paresthesia, seizure, spinal cord infarction (Meng 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival irritation, retinal vein occlusion, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment</p></div>
<div class="block coi drugH1Div" id="F155832"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ethinyl estradiol, cyproterone, or any component of the formulation; breast cancer or other estrogen- or progestin-dependent neoplasms (known or suspected); history of or actual thrombophlebitis or thromboembolic disorders, cerebrovascular disorders, or myocardial infarction or coronary arterial disease; severe diabetes with vascular changes; previous or existing hepatic tumors (benign or malignant) or active hepatic disease; history of cholestatic jaundice; pregnancy; undiagnosed abnormal vaginal bleeding; ocular lesions arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual fields; history of otosclerosis with deterioration during pregnancy; concomitant use with other estrogen/progesterone combinations or estrogens or progestins alone; concomitant use with the hepatitis C combination regimen of ombitasvir, paritaprevir, ritonavir, with or without dasabuvir.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F155817"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding irregularities: Use may be associated with amenorrhea, breakthrough bleeding or changes in menstrual flow. Evaluate persistent irregular vaginal bleeding to exclude pregnancy or neoplasm.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cholestasis: Use is not recommended in patients with a history of cholestatic jaundice or jaundice associated with pregnancy. Temporarily discontinue if severe generalized pruritus develops. Discontinue of cholestatic jaundice develops.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic adenomas or carcinomas: Use of estrogen/progestogen combinations is associated with hepatic adenomas and focal nodular hyperplasia (rare); rupture may cause fatal intra-abdominal hemorrhage. Discontinue use and consider the possibility of a hepatic tumor in the presence of severe upper abdominal pain, liver enlargement, or signs of intra-abdominal hemorrhage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid effects: May adversely affect lipid levels, including serum triglycerides. Patients with hypertriglyceridemia may be at increased risk of pancreatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic disorders: Discontinue use if an arterial or venous thromboembolic event occurs (eg, cerebrovascular accident, deep venous thrombosis, myocardial infarction, pulmonary embolism). The risk of venous thromboembolism with cyproterone/ethinyl estradiol appears to be greater than that of levonorgestrel-containing combined oral contraceptives and similar to that of desogestrel- and drospirenone-containing combined oral contraceptives. Progesterone and/or estrogen should not be taken while on this medication. The increased the risk of venous thromboembolism greatest during first year of use. Patients with activated protein C resistance, hyperhomocysteinemia, protein C or S deficiency, prothrombin mutation, antithrombin III deficiency, or antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant) may have increased risk of venous or arterial thromboembolism, or cerebrovascular accident. Discontinue use if patient is immobilized for an extended period of time (eg, following accident, long-term illness); nonhormonal acne therapy should be used until patient is able to resume regular activities.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: Breast cancer is a hormonal sensitive tumor, and the prognosis may be worse with estrogen/progestogen combinations. Use caution when prescribing estrogen/progestin combinations to patients with risk factors for breast cancer or fibrocystic disease of the breast.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with risk factors for coronary artery disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, increasing age, or cigarette smoking); may lead to increased risk for cardiovascular disease. Patients with androgen-related conditions (severe acne, hirsutism) may have an increased cardiovascular risk. Discontinue use if a significant rise in BP occurs at any time during therapy. Patients with concurrent obesity, hypertension, and diabetes should receive alternative acne therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Connective tissue disease: Use with caution; may exacerbate connective tissue disease (eg, systemic lupus erythematosus, rheumatoid arthritis, synovitis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Use with caution in patients with depression; consider alternative therapy if depression recurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use caution in patients with diabetes or prediabetes; monitor closely. Patients with concurrent diabetes, hypertension and obesity should use alternative treatments for acne.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, or cardiac or renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fibroids: Use with caution in patients with fibroids (leiomyomata); discontinue use with sudden enlargement, pain, or tenderness of fibroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallbladder disease: May increase the risk of gallbladder disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Discontinue if jaundice, or severe generalized pruritus develops during therapy or if liver function becomes abnormal.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hereditary angioedema: Estrogens may induce or exacerbate symptoms in patients with hereditary angioedema. Discontinuation of therapy may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: May be used with caution in patients with well controlled hypertension. Monitor BP and discontinue therapy if BP rises significantly. Patients with concurrent diabetes, hypertension and obesity should use alternative treatments for acne.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabolic/Endocrine diseases: Careful evaluation is recommended prior to starting therapy in patients with metabolic or endocrine diseases and when metabolism of calcium and phosphorus is abnormal; monitor regularly as indicated. Patients with concurrent diabetes, hypertension and obesity should use alternative treatments for acne.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Use with caution in patients with a history of migraine. Evaluate new, recurrent, severe, or persistent headaches. Discontinue if severe headache of unknown etiology or worsening of preexisting migraine headaches occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular changes: Use with caution in patients with myopia; progressive astigmatic error, possibly leading to keratoconus, has been observed in some myopic patients receiving estrogen/progesterone. Patients with family history of such disorders may experience rapid advancement of these ocular disorders. Changes in contact lens tolerance or development of visual changes should be evaluated by an ophthalmologist. Discontinue use if loss of vision, papilledema, or ophthalmic vascular lesions occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Body weight: Patients with a combination of diabetes, hypertension and obesity should use alternative treatments for acne.</p>
<p style="text-indent:-2em;margin-left:4em;">• Smoking: Cigarette smoking increases the risk of serious cardiovascular events from estrogen/progestin combinations. This risk increases with age, particularly in patients &gt;35 years of age, and with the number of cigarettes smoked. Patients using this combination should not smoke.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: Whenever possible, drug should be discontinued at least 4 weeks prior to elective surgery; associated with an increased risk of thromboembolism or during periods of prolonged immobilization. Medication should not be restarted until first menstrual period after hospital discharge following surgery.</p></div>
<div class="block prod-avail drugH1Div" id="F11218427"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F52917358"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52866481"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cleo-35: Ethinyl estradiol 0.035 mg and cyproterone 2 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cyestra-35: Ethinyl estradiol 0.035 mg and cyproterone 2 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diane-35: Ethinyl estradiol 0.035 mg and cyproterone 2 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Ethinyl estradiol 0.035 mg and cyproterone 2 mg</p></div>
<div class="block adm drugH1Div" id="F155829"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer at the same time each day. Swallow tablet whole. A missed dose may be taken within the next 12 hours. If &gt;12 hours, discard unused tablet and resume at usual scheduled times.</p></div>
<div class="block admp drugH1Div" id="F52612471"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer at the same time each day. Swallow tablet whole. A missed dose may be taken within the next 12 hours. If &gt;12 hours, discard unused tablet and resume at usual scheduled times.</p></div>
<div class="block hazard drugH1Div" id="F49130957"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Cyproterone and ethinyl estradiol may cause carcinogenicity, teratogenicity, reproductive toxicity, genotoxicity, and has a structural or toxicity profile similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>
<div class="block use drugH1Div" id="F155828"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the US.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne: </b>Treatment of severe acne with associated symptoms of androgenization (including mild hirsutism or seborrhea).</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not for use prior to menarche or post-menopause. Should be used only when acne is unresponsive to topical therapy and oral antibiotic treatments. Should not be used solely for contraception; however, will provide reliable contraception if taken as recommended for approved indications.</p></div>
<div class="block mst drugH1Div" id="F26116833"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F155857"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak)</p></div>
<div class="block dri drugH1Div" id="F155821"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthrax Immune Globulin (Human): Estrogen Derivatives may enhance the thrombogenic effect of Anthrax Immune Globulin (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: Ethinyl Estradiol-Containing Products may enhance the hepatotoxic effect of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Ethinyl Estradiol-Containing Products. Management: Administer ethinyl estradiol-containing products 4 hours prior to the administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Estrogen Derivatives may enhance the adverse/toxic effect of Chlorprothixene. Estrogen Derivatives may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Progestins may enhance the adverse/toxic effect of Chlorprothixene. Progestins may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Estrogen Derivatives may diminish the diagnostic effect of Cosyntropin.  Management: Discontinue estrogen containing drugs 4 to 6 weeks prior to cosyntropin (ACTH) testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Ethinyl Estradiol-Containing Products may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: Ethinyl Estradiol-Containing Products may enhance the hepatotoxic effect of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Maltol: May decrease the serum concentration of Ethinyl Estradiol-Containing Products. Management: Ferric maltol labeling recommends separating administration of ethinyl estradiol-containing products from ferric maltol by at least four hours to minimize the potential for any interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: May increase the serum concentration of Ethinyl Estradiol-Containing Products. Management: Ethinyl estradiol daily dose should not exceed 30 mcg during coadministration with fostemsavir. Monitor patients closely for any evidence of a thromboembolism.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: Ethinyl Estradiol-Containing Products may enhance the hepatotoxic effect of Glecaprevir and Pibrentasvir. Glecaprevir and Pibrentasvir may increase the serum concentration of Ethinyl Estradiol-Containing Products.  Management: Use of glecaprevir/pibrentasvir and products containing more than 20 mcg of ethinyl estradiol is not recommended. Lower dose ethinyl estradiol-containing products may be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Estrogen Derivatives may diminish the therapeutic effect of Growth Hormone Analogs.  Management: Initiate somapacitan at 2 mg once weekly in patients receiving oral estrogens. Monitor for reduced efficacy of growth hormone analogs; increased doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Estrogen Derivatives may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Estrogen Derivatives may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): Estrogen Derivatives may increase the serum concentration of Hydrocortisone (Systemic). Estrogen Derivatives may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulin: Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Ethinyl Estradiol-Containing Products may decrease the serum concentration of LamoTRIgine.  Management: Larger doses of lamotrigine may be needed when combined with ethinyl estradiol. Specific dosing recommendations vary based on other concomitant medications and which medication is being initiated or discontinued. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: Estrogen Derivatives may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 40 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: Estrogen Derivatives may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Estrogen Derivatives may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking estrogen derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Progestins may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking progestins.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Estrogen Derivatives may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Proguanil: Ethinyl Estradiol-Containing Products may decrease serum concentrations of the active metabolite(s) of Proguanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Estrogen Derivatives. Protease Inhibitors may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: Estrogen Derivatives may enhance the adverse/toxic effect of Raloxifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: Ethinyl Estradiol-Containing Products may increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. Ethinyl Estradiol-Containing Products may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: Ethinyl Estradiol-Containing Products may increase the serum concentration of Selegiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Estrogen Derivatives may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Estrogen Derivatives may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: Estrogen Derivatives may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: May diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Estrogen Derivatives may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F155841"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well. Management: Monitor patients closely with concurrent use.</p></div>
<div class="block rep_considerations drugH1Div" id="F53539399"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy should be ruled out prior to treatment.</p>
<p style="text-indent:0em;margin-top:2em;">This product should not be prescribed only for the prevention of pregnancy; however, it will provide reliable contraception if taken as recommended for the approved indications. The risk of venous thromboembolic events may be increased compared to other combination hormonal contraceptives; use of other estrogen/progestogen combination should not be used during treatment with cyproterone/ethinyl estradiol. Patients with uncertain compliance should also use a nonhormonal contraceptive (eg, barrier method) when contraception is needed.</p>
<p style="text-indent:0em;margin-top:2em;">Upon discontinuation of therapy, patients should use a nonhormonal contraceptive to delay pregnancy until at least one normal spontaneous cycle has occurred. Patients with amenorrhea prior to use may remain anovulatory or amenorrheic after discontinuation of therapy.</p>
<p style="text-indent:0em;margin-top:2em;">Additional warnings and precautions associated with combination hormonal contraceptive products should be considered.</p></div>
<div class="block pri drugH1Div" id="F155833"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Feminization of a male fetus is possible. Use is contraindicated in known or suspected pregnancy. Also consider warnings and precautions associated with combination hormonal contraceptive products.</p></div>
<div class="block brc drugH1Div" id="F13218767"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone and ethinyl estradiol are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Based on product labeling, the estimated daily exposure to a breastfed infant is ~0.2% and 0.02% of the daily maternal dose of cyproterone acetate and ethinyl estradiol, respectively. Estrogen/progestogen combinations may reduce milk production. Breastfeeding is not recommended by the manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">Although this product is not primarily indicated for contraception, additional warnings and precautions associated with combination hormonal contraceptive products should be considered.</p></div>
<div class="block mop drugH1Div" id="F155824"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to therapy: Assessment of pregnancy status; BP; physical exam with reference to breasts, liver, extremities, abdomen and pelvic organs; Papanicolaou smear (sexually active patients); urinalysis. Repeat examinations at regular intervals during therapy, including a yearly breast examination.</p>
<p style="text-indent:-2em;margin-left:2em;">The first follow-up visit should be 3 months after initiation of treatment. If a menstrual period is missed, the possibility of pregnancy should be considered. Monitor patient for vision changes; BP; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias. Adequate diagnostic measures should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">The need for continued treatment should be evaluated periodically; discontinue 3 to 4 cycles after resolution of symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">Evaluate hypothalamic-pituitary function in patients with persistent (≥6 months) amenorrhea (especially associated with breast secretion) following discontinuation of therapy.</p></div>
<div class="block pha drugH1Div" id="F155816"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ethinyl estradiol: Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system. Estrogen increases levels of sex hormone-binding globulin (SHBG) and may reduce unbound androgen levels. Ethinyl estradiol is a synthetic derivative of estradiol. The addition of the ethinyl group prevents rapid degradation by the liver. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cyproterone: Steroidal compound with antiandrogenic, antigonadotropic and progestin-like activity.</p></div>
<div class="block phk drugH1Div" id="F155831"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F155834"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Daphne | Diane | Estelle</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Avancel | Diane | Mileva 35 | Tess 35 | Zinnia</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Alisma | Alisma gynial | Bellgyn | Diane | Midane | Minerva</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Brenda-35 | Carolyn 35 ed | Chelsea 35 ed | Diane | Estelle | Jene 35 ed | Juliet-35 | Juliet-35 ED | Laila 35 ED</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cleo | Giane 35</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Claudia | Cyprodiol | Daphne | Daphne continu | Diane | Doccyproestra | Gratiella | Merck Elisa 35 | Ratiopharmeva</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Duopil | Mileva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Chloe | Diane | Melleva</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acetato de ciproterona + etinilestradiol | Acetato de ciproterona+etinilestradiol | Artemidis | Ciprane | Diane | Diclin | Duelle | Dunia | Ferane | Jaque | Leila | Lydian | Repopil | Repopil 35 | Selene | Tess</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cypestra | Cyprelle | Cyproderm | Diane | Feminac 35 | Holgyeme | Minerva | Vroni gynial</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Duopil</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Anuar | Dixi | Drina | Evilin | Flarina 35 | Lady Ten 35 | Lunys 35 | Sop</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Da ying 35 | Diane</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bioface | Cetol | Cyacetin | Diane | Donabella | Facentin | Facentin mini | Facentin suave | Facetix | Facetix mini | Facetix suave | Femicne | Isbela | Linface | Sop</span>;</li>
<li>
<span class="countryCode">(CU)</span> <span class="country">Cuba</span><span class="countrySeparator">: </span><span class="drugName">Estracip</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Diane | Minerva | Vreya</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Attempta | Bella hexal | Clevia | Cyproderm | Cypronette AL | Diane | Ergalea | Jennifer | Juliette | MicypraTM | Morea Sanol</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Cyproteronacetat/ethinylestradiol "Ratiopharm | Dianova | Feminil</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acrea | Aliad | Daniele | Dixi | Eviden | Venisse</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cypress | Diane | Dixi | Dixi suave 30 | Drina | Etinilestradiol | Isbela | Linface | Mileva 35 | Selene</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Attempta ratiopharm | Cypretil | Diane | Femina</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Diane</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acetato de Ciproterona/Etinilestradiol Sandoz | Diane | Gyneplen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cypretyl | Diane | Diane nova | Feminil | Vreya</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cypropharm | Cyproterone/Ethinylestradiol EG | Cyproterone/ethinylestradiol Ranbaxy | Cyproterone/ethinylestradiol ratiopharm | Cyproterone/Ethinylestradiol Sandoz | Cyproterone/ethinylestradiol shering | Diane | Evepar | Holgyeme | Lumalia | Minerva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Acnocin | Clairette | Co cyprindiol | Diane | Dianette | Teragezza</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Gynofen</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cypress | Daphne | Diane | Esdian | Estelle</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Axira 35 | Diane</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bellune | Diane | Minerva</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Diane | Elzsa | Estelle | Estelle 35 ed | Neynna</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dianette</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Diane | Estelle</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Butipil | Carpela | Cypo kare | Diane | Elestra | Elyn | Ethidol c | Evashine | Femiwise | Ginette | Herface | Hersuit | Krimson | Maysun | Mypill</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Diane | Visofid</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Diane</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Diane | Femigirl | Krimson</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Diane</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Diane</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Clairette | Diane</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Chloe | Cypretil | Diane | Femina</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Daphne</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Chloe | Cypretil | Diane | Femina</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Diane | Lumalia</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Angie | Diane | Eunice 35ed | Kelle | Mileva</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cybelle | Cypress | Diane | Estelle | Giane 35 | Sucee</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Cyprodiol | Diane | Dianofem</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cyproteronacetaat/ethinylestradiol | Cyproteronacetaat/ethinylestradiol alpharma | Cyproteronacetaat/Ethinylestradiol CF | Cyproteronacetaat/ethinylestradiol Gf | Cyproteronacetaat/ethinylestradiol Katwijk | Cyproteronacetaat/ethinylestradiol Merck | Cyproteronacetaat/ethinylestradiol mylan | Cyproteronacetaat/ethinylestradiol pch | Cyproteronacetaat/ethinylestradiol ratiopharm | Cyproteronacetaat/ethinylestradiol Sandoz | Diane | Gynofen | Minerva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Diane | Feminil | Zyrona</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Diane | Estelle | Ginet-63 | Ginet-84</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cypress | Darginia | Diane | Dixi | Drina | Evilin | Giane 35 | Isbela | Selene</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Althea | Ancea | Ariane | Crimson | Cybelle | Diane</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Acne heal | Acnot | Allure pacific | C ethin | Cyprodiol | Diane | Divestra | Dyestadiol | Liane</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cyprest | Cyprodiol | Diane | Syndi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acetato de ciproterona + etinilestrad.ariel. | Ciproterona + etinilestradiol | Diane</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Arviolen | Diane | Dixi | Dixi mini | Femigen | Lady ten | Parisatis</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Diane-35</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Chloe | Diane</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bellune | Besamel | Chloe | Diane | Erika | Modell pure</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Diane</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Diane | Zyrona</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Diane | Estelle</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Diane</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Diane | Vreya</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Beriz | Dafne 35 | Dermooth | Diane | Lady-35 | Lady-e35 | Laura 35 | Manoane | Nina | Oc | Sasha | Sucee | Tina</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Diane | Elleacnelle</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Diane | Elleacnelle | Gynelle</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Esdian | Estelle | Lunar | Nortin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Diane | Modell pure</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Genoderm | Sop</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Arbella 35 | Bioface | Ciproterona + etinilestradiol | Dani | Diane | Dixi | Dunia | Galby | Genoderm | Isbela | Lumalia</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Loacne | Prostarin | Ridne</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Diane | Diva 35 | Fem 35 | Ginette | Minerva</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cypress | Diane | Ginette</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Diane</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27590388">
<a name="27590388"></a>Chen CH, Chin HY, Chen HH, Chang HY, Liu WM. Pills-related severe adverse events: a case report in Taiwan. <i>Taiwan J Obstet Gynecol</i>. 2016;55(4):588-590. doi:10.1016/j.tjog.2016.03.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-and-ethinyl-estradiol-united-states-not-available-drug-information/abstract-text/27590388/pubmed" id="27590388" target="_blank">27590388</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cleo-35 (cyproterone acetate and ethinyl estradiol) [product monograph]. Concord, Ontario, Canada: Altius Healthcare Inc; March 2017.</div>
</li>
<li>
<div class="reference">
                  Cyestra-35 (cyproterone acetate and ethinyl estradiol) [product monograph]. St-Laurent, Quebec, Canada: Paladin Labs Inc; January 2019.</div>
</li>
<li>
<div class="reference">
                  Diane-35 (cyproterone acetate and ethinyl estradiol) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; March 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24491473">
<a name="24491473"></a>Kromm J, Jeerakathil T. Cyproterone acetate-ethinyl estradiol use in a 23-year-old woman with stroke. <i>CMAJ</i>. 2014;186(9):690-693. doi:10.1503/cmaj.130579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-and-ethinyl-estradiol-united-states-not-available-drug-information/abstract-text/24491473/pubmed" id="24491473" target="_blank">24491473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25511216">
<a name="25511216"></a>Meng FC, Lee JT, Peng GS, Sung YF. Cervical spinal cord infarction associated with the use of oral contraceptives for the treatment of acne in a healthy young woman. <i>J Postgrad Med</i>. 2015;61(1):36-37. doi:10.4103/0022-3859.147036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-and-ethinyl-estradiol-united-states-not-available-drug-information/abstract-text/25511216/pubmed" id="25511216" target="_blank">25511216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25878392">
<a name="25878392"></a>Sharmila V, Babu TA. Oral contraceptive pills induced hemichorea in an adolescent female with polycystic ovarian disease. <i>Indian J Pharmacol.</i> 2015;47(2):232-233. doi:10.4103/0253-7613.153440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-and-ethinyl-estradiol-united-states-not-available-drug-information/abstract-text/25878392/pubmed" id="25878392" target="_blank">25878392</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8579 Version 282.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
